Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy-Reference-Cited by-同舟云学术

Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy

Published:2023-10 Issue:10 Volume:29 Page:594-597
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Kanate Abraham S.^ORCID,Majhail Navneet,DeFilipp Zachariah^ORCID,Dhakal Binod^ORCID,Dholaria Bhagirathbhai,Hamilton Betty,Herrera Alex F.^ORCID,Inamoto Yoshihiro,Jain Tania^ORCID,Perales Miguel-Angel^ORCID,Carpenter Paul A.,Hamadani Mehdi^ORCID

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference38 articles.

1. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation;Majhail;Biol Blood Marrow Transplant,2015

2. Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy;Kanate;Biol Blood Marrow Transplant,2020

3. Clinical utilization of chimeric antigen receptor T cells in B cell acute lymphoblastic leukemia: an expert opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation;Kansagra;Biol Blood Marrow Transplant,2019

4. Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy;Jain;Biol Blood Marrow Transplant,2019

5. US Food and Drug Administration. Approved cellular and gene therapy products. Available at: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products. Accessed March 4, 2023.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world treatment of large B‐cell lymphoma with chimeric antigen receptor T‐cell therapy after loncastuximab tesirine;eJHaem;2024-09-02

2. Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation;Transplantation and Cellular Therapy;2024-09

3. Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention;Blood Advances;2024-08-15

4. Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas;Blood Advances;2024-08-02

5. Mobilizing CARs: Benefits, Drawbacks, and Directions for Outpatient CAR T-cell therapy;Seminars in Hematology;2024-08